Compounds, isomer thereof, or pharmaceutically acceptable...

Details Compounds, isomer thereof, or pharmaceutically acceptable... Compounds, isomer thereof, or pharmaceutically acceptable...

2007-07-27

2010-12-28

Davis, Zinna N (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S253010, C514S318000, C514S343000, C514S351000, C514S352000, C514S357000, C544S131000, C544S360000, C546S194000, C546S278400, C546S300000, C546S309000, C546S337000

Reexamination Certificate

active

07858621

ABSTRACT:
This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same.The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.

REFERENCES:
patent: 02/16318 (2002-02-01), None
patent: 03/049702 (2003-06-01), None
patent: 2005/003084 (2005-01-01), None
patent: 2006/051378 (2006-05-01), None
patent: 2006-095263 (2006-09-01), None
patent: 2006-097817 (2006-09-01), None
patent: 2006-098554 (2006-09-01), None
patent: 2006-101318 (2006-09-01), None
patent: 2006-101321 (2006-09-01), None
Mezey et al., “Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human”, PNAS, Mar. 28, 2000, vol. 97(7), 3655-3660.
Cortright et al., “The Tissue Distribution and Functional Characterization of Human VR1”, Biochemical and Biophysical Research Communications, vol. 281(5), 2001, 1183-1189.
Nagy et al., “The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology”, European Journal of Pharmacology 500 (2004), 351-369.
Petersen et al., “Capsaicin evoked pain and allodynia in post-herpetic neuralgia”, Pain 88 (2000) 125-133.
Walker et al., “The VR1 Antagonist Capsazepine Reverses Mechanical Hyperalgesia in Models of Inflammatory and Neuropathic Pain”, The Journal of Pharmacology and Experimental Therapeutics, vol. 304(1), 2003, 56-62.
Akerman et al., “Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors”, British Journal of Pharmacology (2004) 142(8), 1354-1360.
Kim et al., “Transient Receptor Potential Vanilloid Subtype 1 Mediates Cell Death of Mesencephalic Dopaminergic Neurons In Vivo and In Vitro”, The Journal of Neuroscience, Jan. 19, 2005, vol. 25(3), 662-671.
Kamei et al., “Role of vanilloid VR1 receptor in thermal allodynia and hyperalgesia in diabetic mice”, European Journal of Pharmacology 422 (2001), 83-86.
Chan et al., “Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency”, The Lancet, vol. 361, Feb. 1, 2003, 385-391.
Yiangou et al., “Vanilloid receptor 1 immunoreactivity in inflamed human bowel”, The Lancet, vol. 357, Apr. 28, 2001, 1338-1339.
Holzer, Peter, “TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia”, European Journal of Pharmacology 500 (2004) 231-241.
Hwang et al., “Hot channels in airways: pharmacology of the vanilloid receptor”, Current Opinion in Pharmacology 2002, vol. 2, 235-242.
Geppetti et al., “The transient receptor potential vanilloid 1: Role in airway inflammation and disease”, European Journal of Pharmacology 533 (2006) 207-214.
Birder et al., “Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1”, Nature Neuroscience, vol. 5(9), Sep. 2002, 856-860.
Birder et al., “Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells”, PNAS, Nov. 6, 2001, vol. 98(23), 13396-13401.
Southall et al., “Activation of Epidermal Vanilloid Receptor-1 Induces Release of Proinflammatory Mediators in Human Keratinocytes”, The Journal of Pharmacology and Experimental Therapeutics, vol. 304(1), 217-222, 2003.
Tominaga et al., “The Cloned Capsaicin Receptor Integrates Multiple Pain-Producing Stimuli”, Neuron, vol. 21, Sep. 1998, 531-543.
Balaban et al., “Type 1 vanilloid receptor expression by mammalian inner ear ganglion cells”, Hearing Research 175 (2003), 165-170.
Scotland et al., “Vanilloid Receptor TRPV1, Sensory C-Fibers, and Vascular Autoregulation”, Circulation Research, Nov. 12, 2004, vol. 95, 1027-1034.
Bodo et al., “A Hot New Twist to Hair Biology, Involvement of Vanilloid Receptor-1 (VR1/TRPV1) Signaling in Human Hair Growth Control”, American Journal of Pathology, vol. 166(4), Apr. 2005, 985-998.
Biro et al., “Hair Cycle Control by Vanilloid Receptor-1 (TRPV1): Evidence from TRPV1 Knockout Mice”, Journal of Investigative Dermatology (2006), vol. 126, 1909-1912.
Dinis et al., “Anandamide-Evoked Activation of Vanilloid Receptor 1 Contributes to the Development of Bladder Hyperreflexia and Nociceptive Transmission to Spinal Dorsal Horn Neurons in Cystitis”, The Journal of Neuroscience, Dec. 15, 2004, vol. 24(50), 11253-11263.
Sculptoreanu et al., “Protein kinase C contributes to abnormal capsaicin responses in DRG neurons from cats with feline interstitial cystitis”, Neuroscience Letters 381 (2005), 42-46.

Affiliated with

Also associated with

Rating

Compounds, isomer thereof, or pharmaceutically acceptable... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds, isomer thereof, or pharmaceutically acceptable..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds, isomer thereof, or pharmaceutically acceptable... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4219561